Table 1.
Anthropometric and Biochemical Parameters of Patients at Baseline and Months 1 and 3
| LGH (n = 8) |
Placebo (n = 9) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 3 | δMonth 3 − Baseline | Baseline | Month 1 | Month 3 | δMonth 3 − Baseline | |
| Gender, male/female | 3/5 | 4/5 | ||||||
| Age, y | 40.3 (3.7) | 38.1 (4.3) | ||||||
| Waist circumference, cm | 111.2 (6.8) | 113.3 (6.2) | 111.0 (5.7) | −0.2 (2.4) | 107.2 (9.3) | 108.8 (8.0) | 110.7 (9.1) | 2.9 (1.5) |
| BMI, kg/m2 | 35.7 (3.9) | 35.8 (3.9) | 35.9 (3.9) | 0.2 (0.2) | 34.2 (3.6) | 34.4 (3.6) | 35.0 (3.7) | 0.8 (0.4) |
| Body weight, kg | 104.4 (14.4) | 104.9 (14.4) | 100.1 (11.0) | −4.3 (4.8) | 99.0 (12.6) | 99.6 (12.9) | 101.1 (13.0) | 2.0 (1.2) |
| Glucose, mg/dL | 79.7 (5.2) | 80.1 (4.9) | 76.5 (3.3) | −3.2 (3.7) | 77.8 (4.5) | 76.2 (4.4) | 83.0 (4.8) | 5.2 (4.0) |
| Insulin, mIU/L | 15.7 (4.8) | 16.5 (4.4) | 13.9 (4.8) | −3.8 (2.6)a | 6.8 (1.1) | 10.6 (2.7) | 9.6 (2.3) | 2.8 (1.4) |
| C-peptide, ng/mL | 3.1 (0.8) | 3.9 (1.1) | 3.2 (1.1) | 0.1 (0.4) | 2.2 (0.4) | 2.7 (0.5) | 2.9 (0.5) | 0.7 (0.2) |
| FFA, mmol/L | 0.67 (0.08) | 0.65 (0.07) | 0.56 (0.09) | −0.24 (0.11) | 0.61 (0.07) | 0.66 (0.06) | 0.59 (0.09) | −0.02 (0.09) |
| Adiponectin, mg/L | 9.4 (2.1) | 10.1 (2.3) | 9.9 (2.0) | −0.9 (0.9) | 9.2 (1.0) | 9.8 (1.2) | 10.2 (1.1) | 1.0 (0.8) |
| IGF-1, μg/L | 86.1 (15.6) | 100.0 (14.3) | 110.4 (21.2) | 24.3 (13.1) | 75.8 (12.4) | 92.9 (16.1) | 95.8 (15.4) | 20.0 (8.7) |
| IGF-1 KIRA, μg/L | 0.52 (0.13) | 0.41 (0.07) | 0.44 (0.09) | −0.08 (0.09) | 0.71 (0.16) | 0.82 (0.15) | 0.94 (0.21) | 0.23 (0.13) |
| IGF-2, μg/L | 409.6 (39.6) | 455.8 (38.9) | 381.7 (24.8) | −8.0 (16.7) | 415.9 (40.6) | 424.6 (48.6) | 415.8 (40.6) | −0.1 (17.4) |
| IGFBP-2, μg/L | 145.0 (27.2) | 184.5 (43.3) | 163.0 (43.2) | −2.8 (16.3) | 144.2 (47.0) | 140.9 (31.9) | 103.3 (16.6) | −40.9 (34.1) |
| IGFBP-3, mg/L | 4.13 (0.43) | 4.48 (0.38) | 3.91 (0.41) | −0.22 (0.20)a | 3.70 (0.49) | 4.20 (0.53) | 4.07 (0.53) | 0.37 (0.19) |
| IGF-1 to IGFBP-3 molar ratio, % | 7.44 (0.96) | 8.22 (0.72) | 10.42 (1.76)b | 2.98 (1.24) | 7.50 (0.90) | 8.01 (1.15) | 8.61 (1.24) | 1.12 (0.82) |
| IGF-2 to IGFBP-3 molar ratio, % | 38.4 (0.9) | 39.4 (1.2) | 40.2 (1.6) | 1.5 (2.2) | 46.4 (3.3) | 40.1 (1.5) | 40.8 (2.0) | −5.5 (2.3) |
| IGF-1 + IGF-2 to IGFBP-3 molar ratio, % | 45.9 (1.0) | 47.6 (1.2) | 49.0 (1.9) | 3.4 (2.0) | 53.9 (3.2) | 48.1 (1.8) | 49.4 (1.8) | −4.4 (2.8) |
Data are presented as mean (SE), except for data on gender. Bold values indicate statistical significance of the data.
a
P < .05 vs placebo δmonth 3 − baseline.
b
P < .05 vs LGH baseline.